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Synopsis
Iron, an essential nutrient, is required for many diverse biological processes. The absence of a defined pathway to
excrete excess iron makes it essential for the body to regulate the amount of iron absorbed; a deficiency could lead
to iron deficiency and an excess to iron overload and associated disorders such as anaemia and haemochromatosis
respectively. This regulation is mediated by the iron-regulatory hormone hepcidin. Hepcidin binds to the only known iron
export protein, ferroportin (FPN), inducing its internalization and degradation, thus limiting the amount of iron released
into the blood. The major factors that are implicated in hepcidin regulation include iron stores, hypoxia, inflammation
and erythropoiesis. The present review summarizes our present knowledge about the molecular mechanisms and
signalling pathways contributing to hepcidin regulation by these factors.
Key words: erythropoiesis, hepcidin, hypoxia, inflammation, iron.
Cite this article as: Bioscience Reports (2015) 35, e00192, doi:10.1042/BSR20150014
HEPCIDIN
Iron is an essential element for many biological processes and
hence it is required for the survival of all living organisms. Iron
can also be toxic in excess and its misregulation is the basis for
many clinical disorders. Soon after its identification in 2000, it
was realized that the liver-expressed peptide hepcidin plays a
central role in the systemic regulation of iron metabolism; its
imbalance or aberrant expression was found to be at the centre of
many iron disorders. Aptly, it has been described as the master
regulator of iron metabolism and the iron regulatory hormone.
Hepcidin was originally identified as a liver-expressed antimi-
crobial peptide (LEAP1) with direct antimicrobial activity against
a number of bacterial and fungal species [1,2]. It was soon dis-
covered that hepcidin plays a major role in the regulation of iron
homoeostasis, being overexpressed in the livers of mice with an
induced (dietary or parenteral) iron overload [3]. Disruption of
the gene in mice also resulted in iron overload, further confirming
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its importance in iron metabolism [4]. Hepcidin acts as a negative
regulator of iron stores; in response to increased iron levels, the
liver increases hepcidin synthesis which then acts on the sites
of absorption (enterocytes of the duodenum), storage (primarily
hepatocytes of the liver) or recycling (macrophages of the reticu-
loendothelial system) leading to a decrease in the release of iron
from these tissues.
Hepcidin exerts its influence by binding to and inducing the
internalization and degradation of ferroportin (FPN), the only
known exporter of iron [5]. Given that iron plays an important role
in a variety of cellular, metabolic and physiological processes,
it is not surprising that hepcidin itself is regulated in response
to a wide range of external and internal stimuli. Some of the
best studied of these stimuli include tissue iron stores, transferrin
(TF) saturation, hypoxia and inflammation. In addition, it is also
known that the erythropoietic demand reduces hepcidin levels to
increase iron availability for the production of red blood cells, but
the molecular details of this mechanism are still to be deciphered
[6].
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IRON REGULATORY DISORDERS AND
HEPCIDIN
Either too little or too much iron can have detrimental effects
on health, leading to iron deficiency anaemia on the one hand
and iron overload or haemochromatosis on the other. Heredit-
ary haemochromatosis (HH) is caused by mutations in genes
involved in the regulation of iron metabolism, resulting in ex-
cess iron accumulation in tissues and consequent damage, mani-
festing as fatigue, liver disease, diabetes mellitus, arthropathy,
hypogonadism and/or cardiomyopathy [7]. The gene encoding
HFE (haemochromatosis protein) is mutated in the majority of
patients with HH (type 1 [8]). Two juvenile forms of HH have
been described that are caused by mutations in the genes encod-
ing haemojuvelin (HJV) (HFE2; type 2A) [9] or hepcidin itself
(HAMP, hepcidin anti-microbial peptide; type 2B) [10]. Another
adult onset form of HH (type 3) is caused by mutations in the
gene encoding TF receptor 2 (TFR2) [11]. An autosomal dom-
inant form of iron overload is caused by mutations in the gene
encoding the iron exporter and hepcidin receptor FPN (SLC40A1,
solute carrier family 40 member 1) [12,13]. All these forms of
iron overload can be attributed to defects or imbalances in the
hepcidin–FPN axis that controls iron homoeostasis leading to
iron overload. Anaemia can also be caused by imbalances in the
hepcidin–FPN axis. For example, a form of iron refractory iron
deficiency anaemia (IRIDA) can be caused by mutations in the
gene encoding matriptase-2 [transmembrane protease, serine 6
(TMPRSS6)], a negative regulator of hepcidin [14–16]. The an-
aemia of chronic disease (ACD) has also been linked to increased
expression of hepcidin [17]. The study of these iron-associated
disorders has greatly increased our understanding of how iron
homoeostasis and hepcidin are regulated and the signalling path-
ways involved.
In the following sections, we review the known and poten-
tial signalling pathways and molecules that influence hepcidin
synthesis and hence iron metabolism.
POSITIVE REGULATORS OF HEPCIDIN
The two major stimuli that are known to increase hepcidin syn-
thesis in the liver are body iron status and inflammation.
Iron-mediated hepcidin regulation
The BMP–SMAD pathway
The high expression of hepcidin in hepatocytes and studies into
its regulation has pin-pointed the liver as the control centre for
the regulation of systemic iron homoeostasis. The most com-
monly studied pathway that influences hepcidin transcription in
response to an increase in body iron levels is the bone morpho-
genetic protein (BMP)–sma and mother against decapentaple-
gic (SMAD) pathway. BMPs belong to the transforming growth
factor-β (TGF-β) superfamily of cytokines. They have been
shown to play crucial roles in development, cell proliferation,
cell differentiation and apoptosis. It is now well established that
the BMP–SMAD pathway has a central role in the regulation of
hepcidin in response to body iron levels [18].
The link between the SMAD pathway and iron metabolism
was discovered when it was shown that mice with hepatocyte-
specific deletion of Smad4, develop severe iron overload [19]. The
livers of these mice had a 100-fold suppression of Hamp mRNA
levels, suggesting that SMAD4 is involved in the transcriptional
regulation of Hamp [19]. It was proposed that the TGF-β–BMP
pathway was involved in hepcidin regulation, as wild-type hep-
atocytes showed an increase in Hamp mRNA levels in response
to treatment with TGF-β or BMP4, whereas this response was
abrogated in Smad4− / − hepatocytes [19].
More recently it has been shown in mice that BMP6 is the pre-
dominant BMP ligand responsible for hepcidin regulation in vivo
[20–22]. Initially it was shown that in mice the Bmp6 transcript
was regulated similarly to hepatic Hamp in response to different
dietary iron conditions [20]. Subsequent studies demonstrated
that Bmp6 null mice develop a rapid and massive accumulation
of iron in the liver that is related to a marked reduction in liver
Hamp expression [21,22]. It was also shown that the nuclei of the
hepatocytes of Bmp6 null mice had less phospho-SMAD1/5/8
(pSMAD1/5/8) compared with wild-type mice fed a control diet
or an iron-enriched diet [21], indicating that it is a defect in the
BMP–SMAD signalling pathway that is responsible for reduced
hepcidin transcription. Mice treated with BMP6 showed a dose-
dependent reduction in serum iron and TF saturation along with
an increase in hepatic Hamp expression, further supporting the
concept that BMP6 is required for proper Hamp regulation [22].
Molecules involved in BMP–SMAD-mediated regulation of
hepcidin
A major breakthrough was made when it was shown that HJV,
the protein mutated in the majority of cases of juvenile HH, acts
as a BMP co-receptor [23]. This confirmed the role of HJV in
hepcidin regulation and was consistent with reports showing that
patients with type 2A HH had low hepcidin levels [9]. It was
also shown that HJV acted through the BMP pathway rather than
the TGF-β pathway since the presence or absence of HJV did
not affect the activity of a TGF-β responsive promoter element
[23]. Hepatocytes lacking HJV had a blunted response to BMP2
treatment, indicating that HJV acts through or plays a role in
the BMP–SMAD signalling pathway [23]. Using primary hep-
atocytes from mice and a hepatoma cell line, it was shown that
BMP2, 4 and 9 can induce hepcidin transcription independently
of Hfe, Tfr2 or Il6 (interleukin 6). It was also suggested that
BMP9 is the most potent stimulator of hepcidin [24]. Treatment
of mice with BMP2 also lowered hepcidin expression in the liver
and serum iron levels [25]. These results suggested that BMP–
SMAD signalling is an important pathway in the regulation of
iron homoeostasis.
The suggestion that the liver-expressed Tmprss6 acts as an
upstream regulator of the BMP–SMAD pathway added another
layer to this complex regulatory pathway [26]. Patients and mice
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with mutations in the TMPRSS6 gene develop IRIDA. It was
demonstrated that the cause of this anaemia is high levels of
hepcidin [14–16]. Silvestri et al. [26] showed that matriptase-2
cleaved HJV and consequently suppressed signalling through
the BMP–SMAD pathway resulting in reduced transcription of
Hamp. In a recent study, it was shown that decreased intracellular
iron levels lead to an increase in TMPRSS6 protein levels in
HepG2 cells [27]. TMPRSS6 protein levels increased due to a de-
crease in the lysosomal-mediated degradation of the protein and
not due to increased Tmprss6 mRNA levels [27]. These results
suggest a novel iron-mediated regulation of TMPRSS6 protein.
The liver is thought to be the centre for systemic iron regula-
tion and it is believed to mediate this regulation by modulating the
amount of HAMP produced in response to body iron status. The
control of hepcidin expression involves molecules that can sense
the circulating levels of iron and relay these messages through
signal transduction pathways to the nucleus to regulate hepcidin
transcription. Thought to be central to this iron sensing mechan-
ism are the HH-related proteins HFE and TFR2 and the classical
TFR1. It has been suggested that the interactions between these
molecules are important for cells to sense the levels of holo-TF.
Early studies linked HFE, an atypical MHC (major histocompat-
ibility complex) class I protein to iron metabolism by identifying
an interaction with TFR1 [28,29]; however, the mechanism re-
sponsible for regulating iron homoeostasis was not immediately
apparent. With increasing levels of holo-TF, HFE is displaced
from the HFE–TFR1 complex, a step thought to be important for
initiating a signalling cascade that results hepcidin transcription
[30].
The interaction of HFE with TFR1 has been well charac-
terized and the domains and amino acids responsible for this
interaction have been mapped [28,31]. Initial studies failed to de-
tect an interaction between the extracellular domains of human
HFE and TFR2 [32]. However, later work, involving overex-
pression of HFE and TFR2 in cell lines was able to detect an
interaction between these two proteins [33,34]. The formation
of a multi-protein complex (consisting of HFE, TFR2, HJV) at
the surface of the hepatocytes has also been suggested [35]. In
contrast with these studies, other studies using Hfe− / − –Tfr2− / −
double knockout mice [36] and transgenic mice overexpressing
myc-tagged Hfe [37] have suggested that HFE and TFR2 need not
interact to regulate hepcidin synthesis. In support of this, using
the recently developed proximity ligation assay, we also failed
to detect an interaction between these two proteins, in a mouse
hepatoma cell line stably expressing both HFE and TFR2 [38].
HFE and TFR2 are also thought to modulate hepcidin expres-
sion through pathways related to BMP–SMAD. Hfe− / − mice and
humans with HFE-related HH have been shown to have deficien-
cies in BMP–SMAD signalling despite appropriately increased
levels of BMP6 [39–41]. These studies suggested that HFE is
involved in modulating BMP–SMAD signalling downstream of
BMP6. Consistent with this, a recent study demonstrated that
HFE interacts with the BMP type I receptor ALK3 (activin-like
kinase 3), stabilizing the protein at the cell surface and enhan-
cing BMP signalling to increase hepcidin expression [42]. TFR2
deficient mice have also been shown to have reduced levels of
pSMAD1/5/8 in the liver suggesting that TFR2 also modulates the
BMP–SMAD pathway to regulate hepcidin [43]. It was recently
suggested that TFR2 is involved in the up-regulation of BMP6 by
iron and that inappropriately low BMP6 levels in Tfr2− / − mice
may be responsible for reduced BMP–SMAD signalling and low
hepcidin [44]. On the basis of these recent advances, we propose
a new model for the roles of HFE and TFR2 in the regulation
of HAMP. In response to increased TF saturation TFR2 initi-
ates a signalling cascade which results in the synthesis of BMP6.
BMP6 protein is then secreted and interacts with the BMP recept-
ors (BMPRs). HFE is required to transport BMPR type I to the
surface and hence is required for the proper interaction between
BMPs and their receptors. In the absence of a functional TFR2,
BMP6 is not produced appropriately in response to increased iron
levels and hence results in an inappropriate HAMP response. In
the absence of a functional HFE, the type I BMPR is not prop-
erly localized to the surface of hepatocytes resulting in impaired
SMAD signalling and hence inappropriately low HAMP levels.
There appear to be more than one pathway involved in regu-
lation of hepcidin in response to iron levels [45]. The response
to acute and sudden changes in TF saturation (extracellular iron)
seems to involve HFE and TFR2 which presumably sense the
levels of TF saturation and increase the sensitivity of BMPRs
to iron levels [45]. In response to chronic dietary iron overload
Hfe− / − , Tfr2− / − , Bmp6− / − and Hjv− / − , mice showed an in-
crease in hepcidin mRNA levels [45]. This suggests that in addi-
tion to BMP signalling there could be other pathways involved in
regulating hepcidin levels in response to intracellular iron levels
[45].
Regulation of BMP6
In recent years, the BMP–SMAD pathway has been demonstrated
as the predominant pathway responsible for regulating HAMP in
response to iron. Although there have been a number of stud-
ies defining the role of this pathway in the regulation of iron
metabolism, the molecular details of how an increase in iron
levels induce Bmp6 are not known. The liver is a heterogeneous
organ composed of different cell types of which hepatocytes
form approximately 70 % of the cells and the rest comprise non-
parenchymal cells (NPCs), including liver sinusoidal endothelial
cells (LSECs), hepatic stellate cells (HSCs), Kupffer cells (KCs)
and other cells [46]. It has been suggested that in hepatocytes
BMP6 levels correlate with iron stores [47] and are not regulated
by serum iron or TF saturation.
A growing body of evidence suggests a more complicated reg-
ulation of BMP6 in response to increases in iron. It was recently
suggested that BMP6 expression in response to serum iron is
mediated by the NPCs [48] and that ferritin may also be involved
[49]. Bmp6 transcript was predominantly produced in the NPCs,
especially the LSECs and HSCs, indicating that BMP6 could be
acting in a paracrine fashion to influence Hamp transcription in
neighbouring hepatocytes [48].
A few studies have showed that primary hepatocytes can re-
spond to holo-TF treatment [50,51] whereas in previous exper-
iments primary hepatocytes and immortalized hepatocyte cell
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lines did not up-regulate hepcidin in response to holo-TF treat-
ment [17,52]. Results from these and others studies [53,54] have
pointed to an interaction between different cell types in the
liver. Sasaki et al. [26] previously showed that when the human
hepatoma-derived cell line HepG2 was co-cultured with the hu-
man macrophage cell line THP1 (Tamm-Horsfall protein 1) (with
or without contact), they could induce production of HAMP in
response to holo-TF treatment.
These studies suggest that the ‘iron sensing’ role of the liver
could in fact be a function of multiple cell types: the NPCs and the
hepatocytes may sense the iron levels and respond by releasing
BMP6, which then initiates a cascade of events in hepatocytes
leading to the production of hepcidin. This intercellular cross-
talk seems to be one of the mechanisms mediating Bmp6 up-
regulation in response to iron, but the actual molecular pathways
underlying the production of BMP6 in response to either serum
iron or liver iron stores still remain to be identified.
Inflammatory regulation of hepcidin
The second major signalling pathway known to play a role in
the regulation of HAMP transcription is the JAK (Janus kinase)–
STAT3 (signal transducer and activator of transcription 3) path-
way; the stimulus for this regulation coming mainly through
inflammatory cytokines.
Inflammation and iron metabolism
It was known that serum iron levels can be lower in patients with
chronic inflammation and that this can lead to the ACD. The first
insight into how this could be mediated was provided by the dis-
covery of hepcidin’s role in iron metabolism, where Pigeon et al.
[3] showed that treatment of hepatocytes with lipopolysacchar-
ide (LPS) led to an increase in Hamp levels [3]. Subsequently,
using human primary hepatocytes, it was shown that HAMP is a
type II acute phase protein, as it was induced by treatment with
interleukin 6 (IL6) but not with cytokines involved in the type I
response including tumour necrosis factor-α (TNF-α) or IL1α
[17,55]. Further studies established that this response to inflam-
matory signals is not mediated by the KCs in the liver, where
even after depletion of KCs the liver was able to increase hep-
cidin in response to IL6 treatment [56]. Evidence that the HAMP
promoter contains a STAT3-binding site provided further evid-
ence for the mechanism of HAMP regulation during inflammation
[57]. Pietrangelo et al. [58], using transgenic mice in which the
main IL6–gp130 (glycoprotein 130 kD) signalling pathways have
been disrupted, confirmed that STAT3 was the primary transcrip-
tion factor that mediates the IL6 induction of hepcidin [58]. The
JAK–STAT3 pathway works in a similar way to the BMP–SMAD
pathway, where the binding of a cytokine ligand, for example IL6,
to the receptor induces a signalling cascade which results in the
phosphorylation of STAT3 [59]. The phosphorylated STAT3 is
then translocated to the nucleus where it binds to tissue-specific
transcription factors and cofactors to mediate the transcriptional
activation or repression of target genes [59]. Previously, using
a transgenic mouse model with hepatocyte-specific deletion of
STAT3 it was shown that the hypoferremic response to inflamma-
tion, involving hepcidin induction, is mediated directly through
hepatocytes rather than involving other cell types [60].
The increase in hepcidin levels in response to infection seems
to have evolved as a defence mechanism to protect the host from
infections. Most micro-organisms require iron for their growth
and proliferation, hence limiting the release of iron into the blood
by increasing the levels of hepcidin would result in restricted
iron availability to the infectious agent. Indeed some previous
studies have shown results which support this hypothesis. It has
been shown by our laboratory that increased iron stores result in
a worse disease outcome in schistosomiasis [61] and that iron
deficiency leads to better survival rates in children with malaria
[62]. It was shown that in children, iron deficiency decreased
the prevalence of parasitaemia and severe malaria. These results
have initiated a new discussion about the treatment of patients
suffering from the ACD, although the negative consequences of
anaemia can be detrimental to the health of the patients, iron
therapies to counteract iron deficiency may support the pathogen
and lead to worse pathology, hence warranting a closer and more
careful monitoring of such patients.
It has been suggested that there is some interaction/cross-talk
between the BMP–SMAD and the JAK–STAT pathway. Mice
lacking SMAD4 in the hepatocytes did not show an increase in
hepcidin mRNA levels when treated with IL6, suggesting that
the inflammation- and iron-mediated pathways of hepcidin regu-
lation may intersect at SMAD4 [19]. Subsequently, it was shown
that human hepatoma cell lines, zebrafish and mice pre-treated
with a BMP type I receptor inhibitor had a reduced hepcidin
response to IL6 treatment [63]. Recently, it was shown that the
BMP type I receptor Alk3 is required for an IL6-mediated hep-
cidin response [64]. Mice lacking Alk 3 were unable to increase
hepcidin mRNA levels or reduce serum TF saturation in response
to an overexpression of IL6 (injection of adenovirus expressing
IL6) or injection of recombinant murine IL6 [65].
LPS treatment of mice increased SMAD phosphorylation
similarly in the wild-type and Bmp6− / − mice [66]. This up-
regulation of pSMAD1/5/8 levels does not seem to work through
any of the BMP ligands as the mRNA levels of Bmp2, Bmp4,
Bmp5, Bmp6, Bmp7 and Bmp9 did not differ between the control
and LPS challenged mice [66]. The mRNA levels of another TGF-
β superfamily member activin B were shown to be increased in
the animals treated with LPS [66]. Treatment of human hepatoma
cells and mouse primary hepatocytes with activin B induced an
increase in hepcidin mRNA and pSMAD1/5/8 levels [66]. These
observations suggest that activin B could be the BMP ligand in-
volved in the cross-talk between the BMP–SMAD pathway and
inflammation-mediated regulation of hepcidin [66].
There is some evidence suggesting cross-talk between the iron
sensing and the inflammatory pathways regulating hepcidin. Ini-
tially it was shown that HFE is required to mediate the inflam-
matory hepcidin response, as HFE-deficient mice were unable to
increase hepcidin in response to LPS [67]. Later studies contra-
dicted this and suggested that HFE is not required for the LPS-
and IL6-mediated increase in hepcidin transcription [68,69]. In
a previous study published by our laboratory, it was shown that
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mice lacking Tfr2 or both Tfr2 and Hfe have a decreased hypo-
ferremic response after LPS injection [70]. Although these mice
could elevate hepcidin in response to LPS, the inadequate hypo-
ferremic response was attributed to lower levels of basal hepcidin.
NEGATIVE REGULATORS OF HEPCIDIN
Physiological processes like erythropoiesis, which require a con-
stant supply of iron, act as negative regulators of hepcidin. Re-
pression of HAMP is a mechanism to make more iron available
in order to maintain normal homoeostasis.
The erythroid control of hepcidin
One of the most important functions of iron is as an essential
component of the oxygen transporting proteins haemoglobin and
myoglobin. Iron is crucial for the formation and maturation of
red blood cells (erythropoiesis). Anaemia caused by dietary iron
deficiency is one of the most common nutritional disorders in
the world. This requirement for iron suggests that erythropoiesis
itself could be involved in regulating the amounts of bioavailable
iron in the circulation. This was shown to be the case in mouse
studies, where, the suppression of erythropoiesis by irradiation or
post-transfusion polycythaemia dramatically increased the levels
of hepcidin, indicating that erythropoiesis could suppress Hamp
expression [71]. Physiologically, this would be important for the
body in cases of haemorrhage or haemolysis, where there is a
rapid loss of blood and subsequently a huge increase in the de-
mand for iron to produce more red blood cells to alleviate the
condition. In such a situation an increased influx of iron from
the gut and release of iron from the macrophages and liver stores
would be required to keep up with erythropoietic demand. This
can only be maintained if the physiological levels of Hamp are
kept low. This erythroid regulation of Hamp synthesis is be-
lieved to override the regulation by iron stores, as seen in patients
with iron loading anaemias like thalassaemia, where dysregulated
erythropoeisis is able to suppress Hamp even in the presence of
iron overload. This suggests that the proposed ‘erythroid regu-
lator’ [72], which supposedly maintains iron levels in response
to erythropoietic demand exerts its influence by modulating the
levels of hepcidin.
Erythropoietin and hepcidin
One of the main signalling molecules which mediate eryth-
ropoiesis is erythopoietin (EPO); it is produced mainly in the
kidney and is required for proper erythropoiesis, as it helps in the
maturation and development of erythroblasts in the later devel-
opmental stages. When human subjects were treated with EPO
the levels of circulating hepcidin decreased abruptly within 24 h
with the maximal suppression at 72 h, this showed that EPO can
influence hepcidin [73]. In mice treated with inhibitors of eryth-
ropoiesis, increases in EPO levels or treatment with PHZ (phenyl-
hydrazine) does not lead to a suppression of Hamp [74,75]. These
results suggested that although EPO can regulate HAMP, it does
not act directly and therefore cannot be the long sought after
erythroid regulator.
The erythroid regulator
It was hypothesized that this erythroid factor is a molecule
secreted by erythroblasts [76]. Microarray analyses of primary
human erythroblasts were performed to identify the molecules
that respond to this increased demand [76]. These studies iden-
tified two potential erythroid regulators, growth differentiation
factor 15 (GDF15) [76] and twisted gastrulation BMP signalling
modulator 1 (TWSG1) [77]. GDF15 levels in patients suffering
from symptomatic β-thalassaemia were significantly higher than
normal controls [76]. On treating primary human hepatocytes or
HuH7 cells with high concentrations of GDF15 (similar to those
found in patients with thalassaemia) hepcidin transcription was
inhibited [76]. Similarly hepcidin was repressed in cells cultured
in sera from thalassaemic patients [76]. TWSG1 was also shown
to inhibit hepcidin synthesis in HuH7 cells and primary human
hepatocytes by inhibiting BMP–SMAD signalling [77]. Based on
these two studies and the expression pattern of the two molecules
a model was proposed for the inappropriate erythroid regula-
tion of hepcidin in thalassaemia, where TWSG1 (produced in the
early erythroblasts) acts indirectly by inhibiting the BMP–SMAD
pathway and GDF15 which is produced in late erythroblasts acts
directly to inhibit hepcidin, although the signalling mechanism
is unknown [77].
Subsequently it was shown that Gdf15 knockout mice subjec-
ted to two consecutive phlebotomies did not show any differences
in hepcidin levels as compared with the wild-type mice, these
results suggested that either GDF15 is not the putative erythroid
factor or its effects can be overcome by other pathways involved
in hepcidin regulation [78].
The most recent addition to the list of potential erythroid regu-
lators is the product of the Fam132b gene, referred to as erythro-
ferrone (ERFE) [79]. This molecule is also known as myonectin
or C1q/TNF-related protein family member 15 (CTRP15) [79].
ERFE has been proposed to be a stress-erythropoeisis specific
erythroid regulator of hepcidin. Similar to GDF15 and TWSG1,
ERFE is expressed in erythroblasts and after EPO treatment,
the mRNA levels of Fam132b increase only in the erythropoi-
etic organs of adult mice (bone marrow and spleen) [79]. Mice
lacking Fam132b have a blunted suppression of hepcidin in re-
sponse to phlebotomy as compared with wild-type mice suggest-
ing that Fam132b is required for hepcidin suppression after blood
loss [79]. The levels of Fam132b were found to be increased in
mouse models of β-thalassaemia intermedia, again indicating
that it could be playing a role in the suppression of hepcidin
in iron loading anaemias [79]. Recent results from our laborat-
ory using the Tmprss6–Hfe–Tfr2 triple knockout and Tmprss6–
Tfr2 double knockout mice have shown that although Fam132b
levels are higher in these mice, they are unable to suppress Hamp
levels [80]. These results suggest that ERFE could be a potential
erythroid regulator of HAMP in some conditions (thalassaemias)
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and not in others (IRIDA). Although these results are promising
they need to be verified in human studies. The molecular mechan-
isms underlying the action of ERFE are still not known, although
it appears that its regulation of HAMP is not related to the iron
sensing or BMP–SMAD signalling pathway [79].
Hypoxia and hepcidin axis
The main function of the iron in haemoglobin is to bind oxygen;
hence the levels of tissue oxygen depend on the availability of
iron to form haemoglobin. It has long been known that hypoxic
conditions increase erythropoeisis and hence enhance oxygen
availability. Similar to erythropoeisis it was shown that HAMP
levels decrease in hypoxic conditions [81].
Hypoxia-inducible factors and hepcidin regulation
The main mediator of the hypoxic regulation of genes is the
transcription factor hypoxia-inducible factor (HIF). There are
three known subunits of HIF: HIF1α, HIF2α and HIF3α. In the
presence of oxygen, these subunits are modified by prolyl dehyd-
rogenase (PHD) and subjected to proteasomal degradation by
a tumour suppressor, von Hippel-Lindau (VHL) factor [82]. In
oxygen-deprived conditions, PHD is inactivated leading to stabil-
ization of the HIF subunits [82]. The subunits then translocate to
the nucleus and bind the aryl hydrocarbon nuclear receptor trans-
locator or HIF1β (ARNT/HIF1β) forming a heterodimer. The
heterodimers then binds to hypoxia-responsive elements (HREs)
in the DNA and regulate hypoxia-specific target genes, one of
which is EPO.
The first direct evidence for the involvement of HIFs in the
regulation of Hamp was provided in mice with a hepatocyte-
specific deletion of Hif1α [83]. Unlike wild-type mice, these mice
did not show a decrease in Hamp in response to iron deficiency
or hypoxia [83]. The levels of HIF1α in wild-type mice with iron
deficiency were also shown to increase, indicating the importance
of HIF1α in hypoxia-mediated repression of Hamp [83]. Using
ChIP, it was shown that HIF1α binds to three putative HREs in
the Hamp promoter and reduces Hamp expression in both human
cells [human embryonic kidney (HEK)293 cells] and mouse liver
tissues [83]. Using intestinal epithelial cell-specific knockouts of
Hif1α and Hif2α it was demonstrated that Hif2α is required for
iron absorption, as mice lacking Hif2α in the intestinal epithelium
developed a marked iron deficiency, characterized by low liver
and serum iron levels [84]. Interestingly, these mice also had
lower liver Hamp as compared with the wild-type animals [84].
In contrast with these studies which showed a direct effect of the
HIFα subunits on iron metabolism related proteins, another study
suggested that this response is not direct [85]. Although Volke et
al. [85] did get a reduction in Hamp levels in response to hypoxia,
a knockdown of either HIF1α, HIF2α or both did not lead to an
increase in HAMP levels. Interestingly, induction of hypoxia led
to a decrease in TFR2 mRNA levels and this correlated with the
decrease in HAMP [85].
Hypoxia also increases furin mRNA levels through HIF1α
in HepG2 and Hepa-1 (mouse hepatoma) cells [86]. Furin is
a protease that was shown to cleave HJV in the endoplasmic
reticulum to release soluble HJV (sHJV) [87]. sHJV is thought
to be an antagonist to the BMP–SMAD regulation of hepcidin;
it acts by binding to the BMPs and reducing the receptor–ligand
interaction both in vivo and in vitro [25]. Silvestri et al. [87]
also showed that the levels of furin increase in hypoxic and iron-
deficient conditions and hypothesized that this could be one of
the indirect mechanisms of hypoxia-mediated Hamp repression.
Hypoxia was also shown to regulate the levels of TMPRSS6,
which as discussed above, is a negative regulator of BMP–SMAD
signalling [88]. In hypoxic or iron-deficient conditions, the levels
of TMPRSS6 mRNA increased in Hep3B cells, but this increase
was not observed in cells where HIF1α was knocked down,
suggesting that this could be another indirect effect of HIF1α
[88].
Using a hepatocyte-specific Hif2α knockout mouse, it was
shown that in conditions of iron-deficiency HIF2α is not required
for the repression of hepcidin, however mice with a constitutively
active HIF2α (Vhlh/Hif1α double knockout mice) had lower hep-
cidin levels in their livers [89]. Contrary to the results shown by
Silvestri et al. [87] and Lakhal et al. [88], there was no change
in the mRNA levels of Tmprss6 and a decrease in the levels of
furin in these mice. These results suggest that the reduction in
Hamp mRNA levels is not due to a suppression of BMP–SMAD
signalling in these mice. The authors also suggested that this re-
pression is mediated through the increase in erythropoietic drive
in the mice, as an injection of neutralizing erythropoietin serum
over five consecutive days increased Hamp levels [89].
Hypoxia and growth factors
In human volunteers who were subjected to hypoxic conditions
for 6 h, hepcidin levels decreased. The levels of other cytokines
were also measured and surprisingly IL6 levels increased in these
subjects. In addition to this, an increase in platelet-derived growth
factor (PDGF)-BB was also observed [90]. There was a signific-
ant correlation between the increase in PDGF-BB and HAMP
levels suggesting that PDGF-BB could be the hypoxic mediator
of HAMP repression [90]. Treatment with EPO did not increase
levels of PDGF-BB and treatment of normoxic and hypoxic mice
with a PDGF receptor kinase inhibitor increased Hamp levels
in mice, suggesting that hypoxia mediates this effect through the
PDGF pathway [90]. The hypoxic mice did not show any changes
in the levels of pSMAD1/5/8 or pSTAT3, suggesting that the in-
crease in Hamp is not mediated through the BMP–SMAD or the
JAK–STAT pathway [90]. Hypoxic mice exhibited a decrease in
the levels of CAAT enhancer-binding protein α (C/EBPα), cyclic
AMP response element-binding protein (CREB) and CREB-H
[90]. Injection of PDGF-BB did not exhibit a decrease in liver
hepcidin mRNA levels in the CREB-H knockout mice indic-
ating that CREB-H is required for PDGF-BB-mediated down-
regulation of hepcidin [90]. Previously CREB-H has also been
suggested to play a role in endoplasmic reticulum stress-mediated
induction of hepcidin [91].
These studies have added to our understanding about the effect
of hypoxia on iron metabolism. It is now a widely accepted fact
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Regulation of hepcidin
Figure 1 Positive and negative regulators of hepcidin
BMP6, bone morphogenetic protein 6; BMPR-I, bone morphogenetic protein receptor-I; BMPR-II, bone morphogenetic pro-
tein receptor-II; CREB/H, cAMP response-element binding protein/H; EGF, epidermal growth factor; EGFR, epidermal growth
factor receptor; EPO, erythropoietin; EPOR, erythropoietin receptor; ERFE, erythroferrone; GDF15, growth differentiation
factor 15; HFE, hemochromatosis protein; HIF, hypoxia-inducible factor; HJV, hemojuvelin; IL6, interleukin 6; IL-6R, inter-
leukin 6 receptor; JAK, Janus kinase; PDGF-BB, platelet-derived growth factor-BB; PDGFR, platelet-derived growth factor
receptor; SMAD1/5/8, sma and mothers against decapentaplegic homologue 1/5/8 complex; SMAD4, sma and mothers
against decapentaplegic homologue 4; STAT3, signal transducer and activator of transcription 3; TFR1, transferrin receptor
1; TFR2, transferrin receptor 2; TWSG1, twisted gastrulation BMP signaling modulator 1.
that hypoxia increases iron availability by reducing the levels
of hepcidin. The studies mentioned above suggest that there are
many potential mediators and pathways that can mediate the
hypoxic repression of hepcidin. We are still unclear about the
exact molecular mechanisms underlying this repression, whether
it is a direct effect of hypoxia or an indirect consequence through
the increased erythropoietic drive or both is still unclear. It is
also unclear whether it is an effect mediated through HIF1α,
HIF2α or both molecules. The observations that hypoxia can lead
to a change in the transcript and protein levels of iron sensing
molecules (Tfr2, HJV and Tmprss6) also points to a deeper link
between hypoxia and iron metabolism.
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It was also proposed that the repression of HAMP in condi-
tions of hypoxia, anaemia and erythropoeisis is through a com-
mon transcription factor atonal homologue 8 (ATOH8) [92].
ATOH8 expression in HEK293T cells increased SMAD1/5/8
phosphorylation and HAMP levels. Mice treated with EPO, PHZ
or exposed to hypoxia for 24 or 72 h showed a decrease in Atoh8
mRNA and protein levels [92]. Using ChIP, it was shown that
ATOH8 binds to the E-box elements in the HAMP promoter,
hence ATOH8 can potentially regulate HAMP both directly (bind-
ing to the promoter) and indirectly (increasing the phosphoryla-
tion of SMAD 1/5/8 [92].
Other mediators of HAMP regulation
Recent studies have suggested that in addition to the four major
stimuli (iron, inflammation, erythropoiesis and hypoxia) other
factors could regulate HAMP levels as well [93–101].
Growth factors
Growth factors like hepatocyte growth factor (HGF) and epi-
dermal growth factor (EGF) have been shown to inhibit iron and
BMP6 mediated induction of HAMP [93]. Treatment of cells
with HGF or EGF did not change the pSMAD1/5/8 levels but the
amount of pSMAD1/5/8 translocating to the nucleus decreased,
hence resulting in reduced downstream signalling [93].
Hormones
In addition to growth factors, hormones like oestrogen [94] and
testosterone [95–99] have been known to affect HAMP synthesis.
Treatment of cells with 17β-oestradiol (E2) decreased HAMP
levels [94], this was shown to be mediated through direct binding
to the oestrogen-response elements on the HAMP promoter [94].
In another study, it was shown that treatment of HuH7 and HepG2
cells with E2 increases HAMP [100]. Unlike the effects of oestro-
gen, testosterone has been shown to reduce the levels of HAMP
[96]. Until recently, it was unclear whether this down-regulation
is a direct or indirect effect (due to increased erythropoiesis),
when it was shown that even in the presence of an EPO neut-
ralizing antibody, testosterone treatment reduced Hamp levels in
mice [96].
Other signalling pathways
The most recent additions to the list of potential pathways reg-
ulating HAMP have been the Ras–RAF (rapidly accelerated
fibrosarcoma) MAPK (mitogen-activated protein kinase) and
mammalian target of rapamycin (mTOR) pathways [101]. Using
an RNAi screen, components of the Ras–RAF and mTOR path-
way were identified as inhibitors of HAMP synthesis in HuH7
cells [101]. The Ras–RAF pathway is known to be associated
with functions like cell proliferation, cell growth and develop-
ment, whereas the mTOR pathway is also associated with cell
nutrition, oxygen and energy levels [101]. These results emphas-
ize the importance of iron and its regulation, as they link iron
metabolism to basic processes like cell growth and cell energet-
ics.
In summary, hepcidin is the key iron regulatory molecule, re-
sponsible for the regulation of systemic iron homoeostasis. It is
produced predominantly in the liver but can have its effects on
cells in distant locations of the body. As illustrated in Figure 1,
the regulation of this master iron regulator is complex, with a
number of positive and negative regulators. This is probably be-
cause of its wide-ranging roles in modulating iron availability
for various biological processes and in different disease states.
Some of the main regulatory pathways involving iron, inflam-
mation, erythropoiesis, hypoxia, growth factors and hormones
have been studied and the mechanisms of regulation deciphered.
However, there are likely to be many more additional regulatory
factors and pathways that will be uncovered in the future and ce-
ment the place of this small molecule as a major player in many
homoeostatic processes.
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